Saudi Arabia sends first Middle East biological samples into space

Saudi Arabia has sent biological samples from the Middle East into space for the first time. The BioGravity-1 mission launched aboard SpaceX CRS-35 to the International Space Station with NASA support. The Saudi Space Agency and King Abdullah University of Science and Technology lead the work. Two KAUST-developed experiments, SSA-1 and SSA-2, carry reference samples from healthy donors. The goal is a baseline for later studies of Alzheimer’s disease and multiple sclerosis in microgravity. No results, no patient samples and no drug candidates have been reported from this flight. The program is planned in three missions. The first sends healthy reference cells and organoids to establish how they behave in microgravity. The second will use models derived from patients with Alzheimer’s and multiple sclerosis. The third will examine therapeutic responses and look for possible drug targets. Microgravity can change cellular behavior in ways that are hard to reproduce on Earth. Researchers hope those changes will eventually speed insight into disease processes. The current flight does not test treatments. Rayyanah Barnawi, the first Saudi woman to fly in space in 2023, is general supervisor of microgravity research at the Saudi Space Agency and a PhD candidate at KAUST. Samples were prepared at KAUST by researchers including Dr Andrea Diaz Gaxiola in the laboratory of Professor Imed Gallouzi. The cells were frozen and hand-delivered to the National Stem Cell Foundation in California, where they were differentiated into brain-cell types and used to grow organoids. The mission expands an existing National Stem Cell Foundation study of Parkinson’s, primary progressive multiple sclerosis and Alzheimer’s that already includes UK samples from people with an early-onset Alzheimer’s mutation. Axiom Space is the commercial partner. For a hospital or research center in Riyadh or Jeddah the useful distinction is between a baseline flight and a treatment flight. This mission measures healthy cells. Later missions are meant to measure diseased cells and then candidate compounds. A clinician cannot yet order a test or a drug that came from these samples. The samples have only just reached the station. Any finding will have to be repeated on the ground and in patient-derived material before it can affect care. Neurodegenerative disease is a rising priority in Saudi Arabia and across the Gulf. An aging population and better diagnosis increase the number of cases. A space experiment does not change the number of patients today. It adds a research path that uses microgravity as an additional variable. Whether that path produces a usable target depends on the data that return from this flight and from the two that follow. Those data are not yet public. The collaboration links KAUST and the Saudi Space Agency with the National Stem Cell Foundation, Axiom Space and NASA. It also builds local capacity in sample preparation, organoid work and microgravity experiment design. That capacity remains in the Kingdom after the flight ends. The flight itself is one data set. A further limit is the sample type. Healthy donor cells give a reference. They do not show how an Alzheimer’s or multiple sclerosis cell behaves under the same conditions. That comparison is reserved for the second mission. Until those patient-derived models fly, the program has a baseline and a plan. It does not have a disease-specific measurement. Other Gulf research centers can follow the same path once the baseline is public. A lab in Abu Dhabi or Doha that already works on organoids can compare its ground data with the station data when they appear. Until the numbers are released, the comparison cannot be made. The mission adds a Middle East sample set to an existing international study. It does not yet add a Middle East result. Vision 2030 lists research and health among its goals. A flight that returns usable cellular data supports that list. A flight that returns only a press note does not. The difference will be visible when the first measurements are published. If the teams publish the baseline cellular changes observed on the station and a timeline for the patient-sample mission, the program has a next step. If the next line is only another launch announcement, count the measurements that came back and the compounds that were tested. The figure missing is both.